Literature DB >> 2364957

Clinical experience with intra lymphatic administration of 111In-labelled monoclonal antibody PAY 276 for the detection of pelvic nodal metastases in prostatic carcinoma.

H H Abdel-Nabi1, J A Ortman-Nabi, W See, J Lee, R Ireton, M Boileau, M W Unger, C Halverson.   

Abstract

The ability of 111In-PAY 276 (anti prostatic acid phosphatase antibody) in detecting pelvic lymph node metastasis following bipedal intra lymphatic administration was studied in five patients with carcinoma of the prostate. The labeled antibody was injected directly into the lymphatics of each foot. Planar and tomographic images radioactivity content of lymph nodes resected during staging pelvic lymphadenectomy were compared to the histologic and immunoperoxidase findings. Radioactivity in pelvic lymph nodes was prominently seen within 20 min of injection and was present 16 days later. Persistent accumulation of tracer in the lymphatics of the lower extremities was also observed in all patients 16 days post injection. Radioactivity counts in tumor-free lymph nodes were higher than in tumored lymph nodes resected. Our results demonstrate that intra lymphatic administration of 111In-labeled PAY 276 monoclonal antibody has major technical limitations, and that further research directed at the causes of tracer accumulation in the lymphatics and tumor-free lymph nodes is required.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2364957     DOI: 10.1007/bf01146853

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  20 in total

1.  Morbidity from pelvic lymphadenectomy in staging carcinoma of the prostate.

Authors:  D B Paul; S A Loening; A S Narayana; D A Culp
Journal:  J Urol       Date:  1983-06       Impact factor: 7.450

2.  Radiocolloid scintigraphic mapping of the lymphatic drainage of the prostate.

Authors:  W F Whitmore; R D Blute; W D Kaplan; R F Gittes
Journal:  J Urol       Date:  1980-07       Impact factor: 7.450

3.  Phase 1 immunolymphoscintigraphy with an In-111-labeled antimelanoma monoclonal antibody.

Authors:  B L Engelstad; L E Spitler; M J Del Rio; E C Ramos; L L Rosendorf; C E Reinhold; A Khentigan; J P Huberty; S W Corpuz; H M Lee
Journal:  Radiology       Date:  1986-11       Impact factor: 11.105

4.  Clinical stage B prostate carcinoma: staging with MR imaging.

Authors:  P R Biondetti; J K Lee; D Ling; W J Catalona
Journal:  Radiology       Date:  1987-02       Impact factor: 11.105

5.  Preliminary studies of monoclonal antibody lymphoscintigraphy in malignant melanoma.

Authors:  W B Nelp; J F Eary; R F Jones; K E Hellstrom; I Hellstrom; P L Beaumier; K A Krohn
Journal:  J Nucl Med       Date:  1987-01       Impact factor: 10.057

6.  Improved techniques in radionuclide imaging of prostatic lymph nodes.

Authors:  R A Gardiner; J M Fitzpatrick; A R Constable; R W Cranage; E P O'Donoghue; J E Wickham
Journal:  Br J Urol       Date:  1979-12

7.  Optimization of monoclonal antibody delivery via the lymphatics: the dose dependence.

Authors:  M A Steller; R J Parker; D G Covell; O D Holton; A M Keenan; S M Sieber; J N Weinstein
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

Review 8.  Acid phosphatase.

Authors:  M O Henneberry; G Engel; J T Grayhack
Journal:  Urol Clin North Am       Date:  1979-10       Impact factor: 2.241

9.  Radioimaging of the prostate and metastases of prostatic carcinoma with 99mTc-labelled prostatic acid phosphatase-specific antibodies and their Fab fragments.

Authors:  P Vihko; J Heikkilä; M Kontturi; L Wahlberg; R Vihko
Journal:  Ann Clin Res       Date:  1984

10.  Radioimmunodetection of prostatic cancer. In vivo use of radioactive antibodies against prostatic acid phosphatase for diagnosis and detection of prostatic cancer by nuclear imaging.

Authors:  D M Goldenberg; F H DeLand; S J Bennett; F J Primus; M O Nelson; R C Flanigan; J W McRoberts; A W Bruce; D E Mahan
Journal:  JAMA       Date:  1983-08-05       Impact factor: 56.272

View more
  3 in total

1.  Assessment of free dye in solutions of dual-labeled antibody conjugates for in vivo molecular imaging.

Authors:  Melissa B Aldrich; Xuejuan Wang; Amy Hart; Sunkuk Kwon; Lakshmi Sampath; Milton V Marshall; Eva M Sevick-Muraca
Journal:  Mol Imaging Biol       Date:  2011-02       Impact factor: 3.488

Review 2.  Capromab pendetide. A review of its use as an imaging agent in prostate cancer.

Authors:  H M Lamb; D Faulds
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923

Review 3.  Near infrared fluorescent optical imaging for nodal staging.

Authors:  Lakshmi Sampath; Wei Wang; Eva M Sevick-Muraca
Journal:  J Biomed Opt       Date:  2008 Jul-Aug       Impact factor: 3.170

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.